<DOC>
	<DOCNO>NCT01414426</DOCNO>
	<brief_summary>This randomized phase II trial study well vandetanib work prevent head neck cancer patient precancerous head neck lesion . Chemoprevention use certain drug keep cancer forming . The use vandetanib may keep cancer form patient premalignant lesion</brief_summary>
	<brief_title>Vandetanib Preventing Head Neck Cancer Patients With Precancerous Head Neck Lesions</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Determine effect ZD6474 ( vandetanib ) compare placebo microvessel density ( MVD ) baseline 3 month patient risk oral squamous cell carcinoma ( OSCC ) preneoplastic lesion . SECONDARY OBJECTIVES : I . Change MVD 6 month . II . Change putative target ZD6474 : tissue analyze immunohistochemistry ( IHC ) phosphorylated epidermal growth factor receptor ( pEGFR ) , EGFR , phosphorylated-vascular endothelial growth factor receptor 2 ( pVEGFR2 ) , VEGFR2 . III . Change proliferative index measure Ki-67 IHC . IV . Safety , tolerability , adherence ZD6474 6 month patient risk OSCC . TERTIARY OBJECTIVES : I . Compare OSCC incidence study arm ( ZD6474 placebo ) . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive vandetanib orally ( PO ) daily ( QD ) 6 month . Treatment continue absence disease progression unacceptable toxicity . ARM II : Patients receive placebo PO QD 6 month . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 9 12 month every 6 month 2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Verrucous</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<criteria>Histological/cytological confirmation oral cavity dysplasia one three additional criterion : Prior history OSCC Loss heterozygosity ( LOH ) 3p 9p Expression immunohistochemistry ( IHC ) budding uninhibited benzimidazoles 3 ( BUB3 ) /sex determine region Y ( SOX4 ) Provision inform consent Females child bear age must negative serum pregnancy test within 7 day first dose study drug Patients must take steroid stable dose steroid least 14 day enrollment Patients must Karnofsky Performance Score 70 % History malignancy within last 5 year squamous cell carcinoma head neck ( SCCHN ) superficial nonmelanoma skin cancer ; patient history SCCHN must free active carcinoma Currently receive treatment malignancy Serum bilirubin &gt; 1.5x upper limit reference range ( ULRR ) Creatinine clearance = &lt; 30 mL/minute ( calculate CockcroftGault formula ) Potassium , &lt; 4.0 mmol/L despite supplementation ; Common Terminology Criteria Adverse Events ( CTCAE ) grade 1 upper limit Magnesium normal range despite supplementation , CTCAE grade 1 upper limit Serum calcium CTCAE grade 1 upper limit ; case serum calcium normal range , 2 option would available : 1 ) calcium adjust albumin obtain substitute measure serum value ; exclusion base adjust albumin value fall normal limit ; 2 ) Determine ionize calcium level ; ionize calcium level normal range despite supplementation , patient must exclude Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 × ULRR Alkaline phosphatase ( ALP ) &gt; 2.5 x ULRR Evidence severe uncontrolled systemic disease concurrent condition Investigator 's opinion make undesirable patient participate trial would jeopardize compliance protocol Clinically significant cardiovascular event ( e.g . myocardial infarction , superior vena cava syndrome [ SVC ] , New York Heart Association [ NYHA ] classification heart disease &gt; 2 within 3 month entry ; presence cardiac disease , opinion Investigator , increase risk ventricular arrhythmia History arrhythmia ( multifocal premature ventricular contraction ( PVCs ) , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) , symptomatic require treatment ( CTCAE grade 3 ) asymptomatic sustain ventricular tachycardia ; atrial fibrillation , control medication exclude QTc prolongation medication require discontinuation medication Congenital long QT syndrome 1st degree relative unexplained sudden death 40 year age Presence leave bundle branch block ( LBBB ) QTc Bazett 's correction unmeasurable ≥450 msec screen electrocardiogram ( ECG ) ; ( Note : If subject QTc interval &gt; = 450 msec screen ECG , screen ECG may repeat twice [ least 24 hour apart ] ; average QTc three screen ECGs must &lt; 450 msec order subject eligible study ) Any concurrent medication know risk induce Torsades de Pointes , investigator 's opinion discontinue Concomitant medication potent inducer ( rifampicin , rifabutin , phenytoin , carbamazepine , phenobarbital St. John 's Wort ) Cytochrome P450 3A4 ( CYP3A4 ) function Hypertension control medical therapy ( systolic blood pressure great 160 mm mercury ( Hg ) diastolic blood pressure great 100 mm Hg ) Currently active diarrhea may affect ability patient absorb ZD6474 tolerate diarrhea Women currently pregnant breastfeed Receipt investigational agent within 30 day prior commence study treatment Previous enrollment randomization treatment present study Major surgery within 4 week incompletely heal surgical incision start study therapy Involvement planning conduct study ( applies Astra Zeneca staff staff study site )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>